BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 411 filers reported holding BIO-TECHNE CORP in Q3 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,614,193 | -16.8% | 67,786 | -0.2% | 0.04% | -14.6% |
| Q2 2023 | $5,543,248 | +109928.7% | 67,907 | +0.0% | 0.04% | +5.1% |
| Q1 2023 | $5,038 | -14.0% | 67,905 | -3.9% | 0.04% | -15.2% |
| Q4 2022 | $5,857 | -99.9% | 70,666 | +300.1% | 0.05% | +7.0% |
| Q3 2022 | $5,016,000 | -16.0% | 17,663 | +2.6% | 0.04% | -17.3% |
| Q2 2022 | $5,969,000 | -19.3% | 17,220 | +0.9% | 0.05% | 0.0% |
| Q1 2022 | $7,392,000 | +20.8% | 17,070 | +5.0% | 0.05% | +13.0% |
| Q4 2021 | $6,120,000 | -23.0% | 16,260 | -0.9% | 0.05% | -4.2% |
| Q3 2021 | $7,952,000 | +7.6% | 16,410 | 0.0% | 0.05% | +4.3% |
| Q2 2021 | $7,389,000 | +13.1% | 16,410 | -4.1% | 0.05% | +12.2% |
| Q1 2021 | $6,535,000 | +19.6% | 17,110 | -0.6% | 0.04% | +17.1% |
| Q4 2020 | $5,465,000 | +24.3% | 17,210 | -3.0% | 0.04% | 0.0% |
| Q3 2020 | $4,397,000 | -9.3% | 17,750 | -3.3% | 0.04% | -22.2% |
| Q2 2020 | $4,846,000 | +43.6% | 18,350 | +3.1% | 0.04% | +18.4% |
| Q1 2020 | $3,375,000 | -14.6% | 17,800 | -1.1% | 0.04% | +11.8% |
| Q4 2019 | $3,951,000 | +14.7% | 18,000 | +2.3% | 0.03% | +9.7% |
| Q3 2019 | $3,444,000 | -6.1% | 17,600 | 0.0% | 0.03% | -11.4% |
| Q2 2019 | $3,669,000 | +1.8% | 17,600 | -3.0% | 0.04% | 0.0% |
| Q1 2019 | $3,604,000 | +38.0% | 18,150 | +0.6% | 0.04% | +20.7% |
| Q4 2018 | $2,612,000 | -32.8% | 18,050 | -5.2% | 0.03% | -17.1% |
| Q3 2018 | $3,888,000 | +52.4% | 19,050 | +10.4% | 0.04% | +34.6% |
| Q2 2018 | $2,552,000 | -4.8% | 17,250 | -3.4% | 0.03% | -7.1% |
| Q1 2018 | $2,682,000 | +16.0% | 17,850 | 0.0% | 0.03% | +16.7% |
| Q4 2017 | $2,312,000 | +7.1% | 17,850 | 0.0% | 0.02% | 0.0% |
| Q3 2017 | $2,158,000 | +3.3% | 17,850 | 0.0% | 0.02% | -4.0% |
| Q2 2017 | $2,089,000 | +3.0% | 17,850 | -10.5% | 0.02% | +4.2% |
| Q1 2017 | $2,028,000 | -1.4% | 19,950 | -0.2% | 0.02% | -4.0% |
| Q4 2016 | $2,057,000 | -10.1% | 20,000 | -4.3% | 0.02% | -16.7% |
| Q3 2016 | $2,289,000 | -2.9% | 20,900 | 0.0% | 0.03% | -6.2% |
| Q2 2016 | $2,357,000 | +17.1% | 20,900 | -1.9% | 0.03% | +10.3% |
| Q1 2016 | $2,013,000 | -1.0% | 21,300 | -5.8% | 0.03% | 0.0% |
| Q4 2015 | $2,034,000 | -2.9% | 22,600 | 0.0% | 0.03% | -9.4% |
| Q3 2015 | $2,094,000 | -1.1% | 22,600 | +5.1% | 0.03% | +6.7% |
| Q2 2015 | $2,117,000 | +3.0% | 21,500 | +4.9% | 0.03% | +7.1% |
| Q1 2015 | $2,056,000 | +6.0% | 20,500 | -2.4% | 0.03% | +3.7% |
| Q4 2014 | $1,940,000 | – | 21,000 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |